Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	2.80T
Revenue (ttm)	7.75B
Net Income (ttm)	-21.89B
Shares Out	30.36M
EPS (ttm)	-728.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,482
Average Volume	409,257
Open	91,200
Previous Close	92,100
Day's Range	89,900 - 91,700
52-Week Range	25,450 - 118,400
Beta	0.68
RSI	59.67
Earnings Date	Mar 18, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 18
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.